Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recruiting Phase 2 Trials for Carboplatin (DB00958)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05821088Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaTreatment